Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the recommended phase II dose (RP2D) of
rosuvastatin that can be given in combination with standard erlotinib treatment in patients
with advanced incurable squamous cell cancer and NSCLC.